Your browser doesn't support javascript.
loading
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
Freemantle, Nick; Mollon, Patrick; Meyer, Tim; Cheng, Ann-Lii; El-Khoueiry, Anthony B; Kelley, Robin K; Baron, Ari D; Benzaghou, Fawzi; Mangeshkar, Milan; Abou-Alfa, Ghassan K.
Afiliação
  • Freemantle N; University College London, London, UK. Electronic address: nicholas.freemantle@ucl.ac.uk.
  • Mollon P; Ipsen Pharma SAS, Boulogne-Billancourt, France.
  • Meyer T; University College London, London, UK.
  • Cheng AL; National Taiwan University Hospital and National Taiwan University Cancer Center, Taiwan, Republic of China.
  • El-Khoueiry AB; Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, CA, USA.
  • Kelley RK; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Baron AD; California Pacific Medical Center, San Francisco, CA, USA.
  • Benzaghou F; Ipsen Bioscience, Cambridge, MA, USA.
  • Mangeshkar M; Exelixis, Inc., South San Francisco, CA, USA.
  • Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
Eur J Cancer ; 168: 91-98, 2022 06.
Article em En | MEDLINE | ID: mdl-35487183

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article